ARDELYX (ARDX) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$3.28
+0.3% on the day
-35.2% over 12 months
52-week range $3.26 – $7.99
Share price and insider trades
ARDX closeInsider buyInsider sale
Bought, 12 months$1.9M
Sold, 12 months$4.3M
Insiders buying1
Insiders selling9
ARDELYX insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1.9M and 9 sold $4.3M of ARDX stock on the open market.
Get emailed when insiders cluster-buy stocks like ARDX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ARDX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $697K | 22 |
| Q2 2026 | — | 0 | $1.8M | 23 |
| Q1 2026 | $1.9M | 1 | $1.4M | 27 |
| Q4 2025 | — | 0 | $453K | 6 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit−$853KOn all tracked purchases -43.8%
Summary
Over the past 12 months, 1 ARDELYX, INC. insider reported open-market purchases totaling $1.9M, while 9 insiders reported sales totaling $4.3M. 8 of 78 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ARDX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 6, 2026 | -3.5% | Sold $211K | -18.5%S&P +0.5% | -5.5% |
| Apr 30, 2026 | -5.1% | Sold $262K | +14.5%S&P +1.3% | -12.2% |
| Feb 19, 2026 | -13.2% | None | -14.7%S&P +0.5% | -7.3% |
| Jan 8, 2026 | +0.5% | None | +32.8%S&P +0.7% | -5.4% |
| Oct 30, 2025 | -1.0% | None | +22.2%S&P -0.8% | -4.3% |
| Aug 4, 2025 | -4.2% | None | +18.5%S&P +1.0% | +28.1% |
| May 1, 2025 | +18.6% | None | -25.0%S&P +2.2% | -11.1% |
| Feb 20, 2025 | +15.2% | None | -20.4%S&P -2.1% | +1.4% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 25SEC | Michael RaabCEO, President | Sell | 19,1781,619,792 held (−1%) | $3.86 | $74K | -15.0% | — |
| Aug 25SEC | John E BishopSee Remarks | Sell | 17,281319,564 held (−5%) | $3.86 | $67K | -15.0% | — |
| Aug 25SEC | Michael RaabCEO, President | Sell | 15,9761,647,381 held (−1%) | $3.86 | $62K | -15.0% | — |
| Aug 25SEC | Michael RaabCEO, President | Sell | 15,0091,663,357 held (−1%) | $3.86 | $58K | -15.0% | — |
| Aug 25SEC | James Parker BradyChief Human Resources Officer | Sell | 13,160245,930 held (−5%) | $3.86 | $51K | -15.0% | — |
| Aug 25SEC | Michael RaabCEO, President | Sell | 8,4111,638,970 held (−1%) | $3.86 | $32K | -15.0% | — |
| Aug 25SEC | Laura A WilliamsChief Patient Officer | Sell | 3,486374,709 held (−1%) | $3.86 | $13K | -15.0% | — |
| Aug 25SEC | Eric Duane FosterChief Commercial Officer | Sell | 3,389411,985 held (−1%) | $3.86 | $13K | -15.0% | — |
| Aug 25SEC | Mike KelliherChief Business Officer | Sell | 3,104354,314 held (−1%) | $3.86 | $12K | -15.0% | — |
| Aug 25SEC | Laura A WilliamsChief Patient Officer | Sell | 3,089371,620 held (−1%) | $3.86 | $12K | -15.0% | — |
| Aug 25SEC | Joseph James ReillySee Remarks | Sell | 2,872146,964 held (−2%) | $3.86 | $11K | -15.0% | — |
| Aug 25SEC | Mike KelliherChief Business Officer | Sell | 2,652351,662 held (−1%) | $3.86 | $10K | -15.0% | — |
| Aug 25SEC | Eric Duane FosterChief Commercial Officer | Sell | 2,598415,374 held (−1%) | $3.86 | $10K | -15.0% | — |
| Aug 25SEC | Eric Duane FosterChief Commercial Officer | Sell | 2,575409,410 held (−1%) | $3.86 | $10K | -15.0% | — |
| Aug 25SEC | John E BishopSee Remarks | Sell | 2,469317,095 held (−1%) | $3.86 | $10K | -15.0% | — |
| Aug 25SEC | Laura A WilliamsChief Patient Officer | Sell | 2,430369,190 held (−1%) | $3.86 | $9K | -15.0% | — |
| Aug 25SEC | Mike KelliherChief Business Officer | Sell | 2,002349,660 held (−1%) | $3.86 | $8K | -15.0% | — |
| Aug 25SEC | James Parker BradyChief Human Resources Officer | Sell | 1,976259,090 held (−1%) | $3.86 | $8K | -15.0% | — |
| Aug 25SEC | Laura A WilliamsChief Patient Officer | Sell | 1,734367,456 held (−0%) | $3.86 | $7K | -15.0% | — |
| Aug 25SEC | Susan HohenleitnerCFO | Sell | 1,558227,520 held (−1%) | $3.86 | $6K | -15.0% | — |
| Aug 25SEC | Joseph James ReillySee Remarks | Sell | 1,110145,854 held (−1%) | $3.86 | $4K | -15.0% | — |
| Jul 17SEC | Michael RaabCEO, President | Sell Plan | 41,6681,678,366 held (−2%) | $5.06 | $211K | -35.2% | — |
| Jun 22SEC | Laura A WilliamsChief Patient Officer | Sell Plan | 81,898378,195 held (−18%) | $5.99 | $491K | -45.2% | — |
| Jun 17SEC | Michael RaabCEO, President | Sell Plan | 41,6661,699,200 held (−2%) | $5.67 | $236K | -42.2% | — |
| May 22SEC | Michael RaabCEO, President | Sell | 17,9261,734,061 held (−1%) | $6.27 | $112K | -47.7% | — |
| May 22SEC | Michael RaabCEO, President | Sell | 14,9331,759,848 held (−1%) | $6.27 | $94K | -47.7% | — |
| May 22SEC | Michael RaabCEO, President | Sell | 14,0281,720,033 held (−1%) | $6.27 | $88K | -47.7% | — |
| May 22SEC | Michael RaabCEO, President | Sell | 7,8611,751,987 held (−0%) | $6.27 | $49K | -47.7% | — |
| May 22SEC | Eric Duane FosterChief Commercial Officer | Sell | 3,166422,804 held (−1%) | $6.27 | $20K | -47.7% | — |
| May 22SEC | Mike KelliherChief Business Officer | Sell | 2,900361,766 held (−1%) | $6.27 | $18K | -47.7% | — |
| May 22SEC | Joseph James ReillySee Remarks | Sell | 2,683149,107 held (−2%) | $6.27 | $17K | -47.7% | — |
| May 22SEC | Mike KelliherChief Business Officer | Sell | 2,478357,418 held (−1%) | $6.27 | $16K | -47.7% | — |
| May 22SEC | Eric Duane FosterChief Commercial Officer | Sell | 2,427420,377 held (−1%) | $6.27 | $15K | -47.7% | — |
| May 22SEC | Eric Duane FosterChief Commercial Officer | Sell | 2,405417,972 held (−1%) | $6.27 | $15K | -47.7% | — |
| May 22SEC | John E BishopSee Remarks | Sell | 2,306336,845 held (−1%) | $6.27 | $14K | -47.7% | — |
| May 22SEC | Laura A WilliamsChief Patient Officer | Sell | 2,157432,422 held (−0%) | $6.27 | $14K | -47.7% | — |
| May 22SEC | Laura A WilliamsChief Patient Officer | Sell | 1,911430,511 held (−0%) | $6.27 | $12K | -47.7% | — |
| May 22SEC | Mike KelliherChief Business Officer | Sell | 1,870359,896 held (−1%) | $6.27 | $12K | -47.7% | — |
| May 22SEC | James Parker BradyChief Human Resources Officer | Sell | 1,846261,066 held (−1%) | $6.27 | $12K | -47.7% | — |
| May 22SEC | Laura A WilliamsChief Patient Officer | Sell | 1,503434,579 held (−0%) | $6.27 | $9K | -47.7% | — |
| May 22SEC | Susan HohenleitnerCFO | Sell | 1,455229,078 held (−1%) | $6.27 | $9K | -47.7% | — |
| May 22SEC | Laura A WilliamsChief Patient Officer | Sell | 1,418429,093 held (−0%) | $6.27 | $9K | -47.7% | — |
| May 22SEC | Joseph James ReillySee Remarks | Sell | 1,036149,836 held (−1%) | $6.27 | $6K | -47.7% | — |
| May 19SEC | Michael RaabCEO, President | Sell Plan | 41,6661,774,781 held (−2%) | $6.28 | $262K | -47.8% | — |
| Apr 17SEC | Michael RaabCEO, President | Sell Plan | 41,6681,795,614 held (−2%) | $6.29 | $262K | -47.9% | — |
| Mar 18SEC | Michael RaabCEO, President | Sell Plan | 41,6661,816,448 held (−2%) | $5.84 | $243K | -43.8% | — |
| Feb 25SEC | Michael RaabCEO, President | Sell Plan | 41,6661,836,153 held (−2%) | $6.26 | $261K | -47.6% | — |
| Feb 23SEC | David M MottDirector | Buy | 333,3333,302,918 held (+11%) | $5.84 | $1.9M | -43.8% | — |
| Feb 23SEC | Michael RaabCEO, President | Sell | 40,4011,862,567 held (−2%) | $5.87 | $237K | -44.1% | — |
| Feb 23SEC | Eric Duane FosterChief Commercial Officer | Sell | 9,176427,233 held (−2%) | $5.87 | $54K | -44.1% | — |
| Feb 23SEC | Mike KelliherSee Remarks | Sell | 8,434365,827 held (−2%) | $5.87 | $50K | -44.1% | — |
| Feb 23SEC | Laura A WilliamsSee Remarks | Sell | 7,192437,066 held (−2%) | $5.87 | $42K | -44.1% | — |
| Feb 23SEC | Michael RaabCEO, President | Sell | 5,5761,856,991 held (−0%) | $5.71 | $32K | -42.6% | — |
| Feb 23SEC | Joseph James ReillySee Remarks | Sell | 4,387152,394 held (−3%) | $5.87 | $26K | -44.1% | — |
| Feb 23SEC | John E BishopSee Remarks | Sell | 2,792339,538 held (−1%) | $5.87 | $16K | -44.1% | — |
| Feb 23SEC | James Parker BradyChief Human Resources Officer | Sell | 2,234263,221 held (−1%) | $5.87 | $13K | -44.1% | — |
| Feb 23SEC | Susan HohenleitnerCFO | Sell | 1,786230,780 held (−1%) | $5.87 | $10K | -44.1% | — |
| Feb 23SEC | Eric Duane FosterChief Commercial Officer | Sell | 1,261425,972 held (−0%) | $5.71 | $7K | -42.6% | — |
| Feb 23SEC | Mike KelliherSee Remarks | Sell | 1,159364,668 held (−0%) | $5.71 | $7K | -42.6% | — |
| Feb 23SEC | Laura A WilliamsSee Remarks | Sell | 984436,082 held (−0%) | $5.71 | $6K | -42.6% | — |
| Feb 23SEC | Joseph James ReillySee Remarks | Sell | 602151,792 held (−0%) | $5.71 | $3K | -42.6% | — |
| Feb 23SEC | John E BishopSee Remarks | Sell | 386339,152 held (−0%) | $5.71 | $2K | -42.6% | — |
| Feb 23SEC | James Parker BradyChief Human Resources Officer | Sell | 309262,912 held (−0%) | $5.71 | $2K | -42.6% | — |
| Feb 23SEC | Susan HohenleitnerCFO | Sell | 247230,533 held (−0%) | $5.71 | $1K | -42.6% | — |
| Feb 23SEC | Mike KelliherSee Remarks | Sell | 2364,666 held (−0%) | $5.71 | $11 | -42.6% | — |
| Feb 23SEC | Michael RaabCEO, President | Sell | 21,856,989 held (−0%) | $5.70 | $11 | -42.5% | — |
| Feb 23SEC | Michael RaabCEO, President | Sell | 21,856,986 held (−0%) | $5.70 | $11 | -42.5% | — |
| Feb 23SEC | Joseph James ReillySee Remarks | Sell | 2151,790 held (−0%) | $5.70 | $11 | -42.5% | — |
| Feb 23SEC | Eric Duane FosterChief Commercial Officer | Sell | 1425,971 held (−0%) | $5.71 | $6 | -42.6% | — |
| Feb 23SEC | Michael RaabCEO, President | Sell | 11,856,988 held (−0%) | $5.70 | $6 | -42.5% | — |
| Feb 23SEC | John E BishopSee Remarks | Sell | 1339,151 held (−0%) | $5.70 | $6 | -42.5% | — |
| Feb 23SEC | Eric Duane FosterChief Commercial Officer | Sell | 1425,970 held (−0%) | $5.70 | $6 | -42.5% | — |
| Jan 9SEC | Laura A WilliamsChief Patient Officer | Sell Plan | 50,000361,563 held (−12%) | $6.98 | $349K | -53.0% | — |
| Nov 25SEC | Michael RaabCEO, President | Sell | 46,8871,455,363 held (−3%) | $5.54 | $260K | -40.8% | — |
| Nov 25SEC | Joseph James ReillySee Remarks | Sell | 11,086108,914 held (−9%) | $5.54 | $61K | -40.8% | — |
| Nov 25SEC | Laura A WilliamsChief Patient Officer | Sell | 6,426359,896 held (−2%) | $5.54 | $36K | -40.8% | — |
| Nov 25SEC | Elizabeth A GrammerSee Remarks | Sell | 5,995299,895 held (−2%) | $5.54 | $33K | -40.8% | — |
| Nov 25SEC | Eric Duane FosterChief Commercial Officer | Sell | 5,814295,684 held (−2%) | $5.54 | $32K | -40.8% | — |
| Nov 25SEC | Mike KelliherSee Remarks | Sell | 5,560271,181 held (−2%) | $5.54 | $31K | -40.8% | — |
Insiders at ARDELYX, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| David M MottDirector | $1.9M | — | Feb 23, 2026 | — |
| Michael RaabCEO, President | — | $2.6M | Aug 25, 2026 | — |
| Laura A WilliamsChief Patient Officer | — | $1.0M | Aug 25, 2026 | — |
| Eric Duane FosterChief Commercial Officer | — | $176K | Aug 25, 2026 | — |
| Mike KelliherChief Business Officer | — | $162K | Aug 25, 2026 | — |
| Joseph James ReillySee Remarks | — | $129K | Aug 25, 2026 | — |
| John E BishopSee Remarks | — | $109K | Aug 25, 2026 | — |
| James Parker BradyChief Human Resources Officer | — | $85K | Aug 25, 2026 | — |
| Elizabeth A GrammerSee Remarks | — | $33K | Nov 25, 2025 | — |
| Susan HohenleitnerCFO | — | $27K | Aug 25, 2026 | — |
ARDX stock: common questions
Are ARDELYX, INC. insiders buying ARDX stock?
In the past 12 months, 1 insiders reported open-market purchases of ARDX worth $1.9M. The latest was Director David M Mott bought $1.9M of ARDX at $5.84 — first open-market purchase in our records.
Are ARDELYX, INC. insiders selling ARDX stock?
9 insiders reported sales worth $4.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ARDX's 52-week range?
Over the past year ARDX has traded between $3.26 and $7.99. It last closed at $3.28 on Oct 9, 2026.